Download MendeleySynthesis and biological investigation of peptidomimetic SARS-CoV-2 main protease inhibitors bearing quinoline-based heterocycles at P 3.
Rossi, S., Deidda, G., Fiaschi, L., Ibba, R., Pieroni, M., Dichiara, M., Carullo, G., Butini, S., Ramunno, A., Brogi, S., Lolicato, M., Arrigoni, C., Cabella, N., Bavagnoli, L., Maga, G., Varasi, I., Biba, C., Vicenti, I., Gemma, S., Crespan, E., Zazzi, M., Campiani, G.(2025) Arch Pharm (Weinheim) 358: e2400812-e2400812
- PubMed: 39873316
- DOI: https://doi.org/10.1002/ardp.202400812
- Primary Citation of Related Structures:
9GF7 - PubMed Abstract:
In the last few years, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been the cause of a worldwide pandemic, highlighting the need for novel antiviral agents. The main protease (M pro ) of SARS-CoV-2 was immediately identified as a crucial enzyme for viral replication and has been validated as a drug target. Here, we present the design and synthesis of peptidomimetic M pro covalent inhibitors characterized by quinoline-based P 3 moieties. Structure-activity relationships (SARs) were also investigated at P 1 and P 2 , as well as for different warheads. The binding modes of the designed inhibitors were assessed using X-ray crystallographic and molecular docking studies. The identified M pro inhibitors were tested for their antiviral activities in cell-based assays, and the results were encouraging. The SAR studies presented here can contribute to the future design of improved inhibitors by addressing some of the current or prospective issues regarding M pro inhibitors currently used in therapy.
- Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy.
Organizational Affiliation:
